Caribou Biosciences CEO to speak at BofA 2026 Health Care Conference on May 13

Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that CEO Rachel Haurwitz will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13 in Las Vegas. The event will be webcast and available on Caribou's website for 30 days. Caribou focuses on developing off-the-shelf CAR-T cell therapies like vispacabtagene regedleucel and CB-011 for treating hematologic malignancies, aiming to improve patient access and treatment speed.